During my PhD at the University of New Brunswick, I synthesized a novel cardiac glucopyranoside with high inotropic activity and safety margin, which received a Hoffman-La Roche patent for clinical trials. My laboratory discovered that chaperone protein CHIP inhibits Alzheimer's senile plaque formation by degrading β-secretase/BACE1 through a CHIP-BACE1-p53 feedback loop, reducing amyloid-beta deposits. I demonstrated that gallium complex GaQ₃ induces cancer cell apoptosis via Ca²⁺-signaling-mediated p53 activation and ROS upregulation. My work revealed that CHIP promotes autophagy-mediated degradation of aggregating mutant p53 in hypoxic tumours through chaperone synergy. I pioneered oxygen therapy for hypoxic tumour regression, showing that re-oxygenation at thirty percent oxygen restores wild-type p53 conformation and induces apoptosis without adverse effects. I discovered that wild-type p53 functions as a molecular chaperone, rescuing conformational p53 mutants and causing significant tumour regression. My team developed a manganese-clay hybrid compound that releases molecular oxygen, triggering p53-mediated cancer cell death in hypoxic environments, and established 3D cancer tumour models using biodegradable polyesters (PHAs) that mimic in vivo conditions. Through SCO2 gene therapy combined with conventional drugs, I achieved substantial tumour regression by activating the ASK-1 kinase pathway. I demonstrated that oxygen therapy protects infarcted myocardium by regulating p53 acetylation, switching p53 from promoting death to activating NOS3-mediated survival signals. My research on gold nanoparticles revealed how p53 core domain modifications determine whether cancer cells undergo apoptotic or necrotic death through differential ROS generation patterns.